Peptic Ulcers - Pipeline Review, H2 2014

Date: September 15, 2014
Pages: 44
Price:
US$ 2,000.00 US$ 1,500.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PAE1C737956EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Peptic Ulcers - Pipeline Review, H2 2014’, provides an overview of the Peptic Ulcers’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peptic Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peptic Ulcers and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Peptic Ulcers
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Peptic Ulcers and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Peptic Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Peptic Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Peptic Ulcers
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Peptic Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Peptic Ulcers Overview
Therapeutics Development
Pipeline Products for Peptic Ulcers - Overview
Pipeline Products for Peptic Ulcers - Comparative Analysis
Peptic Ulcers - Therapeutics under Development by Companies
Peptic Ulcers - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Peptic Ulcers - Products under Development by Companies
Peptic Ulcers - Companies Involved in Therapeutics Development
Sequella, Inc.
Takeda Pharmaceutical Company Limited
Yungjin Pharm Ind. Co., Ltd.
Rottapharm SpA
RaQualia Pharma Inc.
Peptic Ulcers - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
vonoprazan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SQ-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itriglumide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Peptic Ulcers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YGD-1710 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptic Ulcers - Recent Pipeline Updates
Peptic Ulcers - Dormant Projects
Peptic Ulcers - Discontinued Products
Peptic Ulcers - Product Development Milestones
Featured News & Press Releases
Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision
Feb 13, 2012: Horizon Pharma Modifies DUEXIS Marketing Authorization Application To Include Recently Approved Manufacturing Site
Jul 27, 2011: Ilyang Pharmaceuticals Obtains Patent For Ilaprazole
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
Mar 01, 2007: Actavis receives approval for Ranitidine syrup in the U.S.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Peptic Ulcers, H2 2014
Number of Products under Development for Peptic Ulcers - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Peptic Ulcers - Pipeline by Sequella, Inc., H2 2014
Peptic Ulcers - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014
Peptic Ulcers - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014
Peptic Ulcers - Pipeline by Rottapharm SpA, H2 2014
Peptic Ulcers - Pipeline by RaQualia Pharma Inc., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Peptic Ulcers Therapeutics - Recent Pipeline Updates, H2 2014
Peptic Ulcers - Dormant Projects, H2 2014
Peptic Ulcers - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Peptic Ulcers, H2 2014
Number of Products under Development for Peptic Ulcers - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Target, H2 2014
Number of Products by Stage and Top 10 Target, H2 2014
Number of Products by Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
Number of Products by Stage and Top 10 Route of Administration, H2 2014
Number of Products by Stage and Top 10 Molecule Type, H2 2014
Skip to top


Gastric Ulcers - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 43 pages
Gastric Ulcers - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 45 pages
Corneal Ulcers - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 39 pages
Peptic Ulcers - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Peptic Ulcers - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: